Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-05-04

No results posted yet for this study

Summary

Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity.

The main question this study looks to answer is:

• Does metformin alter exercise capacity?

Participants will:

* Complete 5 exercise tests on a stationary bike.
* Undergo a body composition test.
* Take metformin and placebo.
* Complete food and symptom logs.

The researchers hypothesize that:

• Metformin will reduce aerobic capacity.

Conditions

  • Exercise Capacity
  • Metformin

Interventions

DRUG

Metformin Hydrochloride

Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.

DRUG

Placebo

Participants will consume metformin or placebo in a randomized order. Participants will complete exercise visits during each treatment phase.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Jason D Allen, PhD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-31
Primary Completion
2026-07-01
Completion
2026-07-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06638671 on ClinicalTrials.gov